Tremelimumab — Drug Intelligence | 35 EU Trials

Filter these 35 trials by condition, phase, country and more.

Open in Search →

35 Registered trials

15 Recruiting

19 Completed trials

21 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 10 Phase II/III: 2 Phase II: 18 Phase I/II: 4 Phase I (Other): 1

Oversight events:

1 serious breach 2 temporary halts 1 corrective measure across 3 trials

View oversight register →

Indications tested

Hepatocellular carcinoma 4 Cholangiocarcinoma 3 Non-small cell lung cancer 3 Lung squamous cell carcinoma metastatic 1 Oesophageal squamous cell carcinoma metastatic 1 Squamous cell carcinoma of the vagina 1 Biliary adenoma 1 Colorectal cancer metastatic 1 Non-small cell lung cancer metastatic 1 Squamous cell carcinoma of the cervix 1 Squamous cell carcinoma of head and neck 1 Bladder cancer 1

Sponsors using this IMP

AstraZeneca AB 12 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 2 Institut Gustave Roussy 2 Klinikum der Universitaet Muenchen AöR 2 AbbVie Deutschland GmbH & Co. KG 1 Amsterdam UMC Stichting 1 Assistance Publique Hopitaux De Paris 1 Biocompatibles UK Limited 1 Centre De Lutte Contre Le Cancer Eugene Marquis 1 Centre Leon Berard 1 ETOP IBCSG Partners Foundation 1 Fondazione GONO G.I. 1

All trials — page 2

35 total

IMMUWHY Ended

2023-508314-42-00 Phase II 2 countries Institut fuer Klinische Krebsforschung IKF GmbH
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Phase III 7 countries AstraZeneca AB
A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri… Ended

2024-510976-19-00 Phase III 6 countries AstraZeneca AB
This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended

2024-512212-21-00 Phase III 4 countries AstraZeneca AB
A clinical trial in patients with advanced liver cancer. The trial will investigate the safety, tolerability and clinical activity of durval… Ended

2024-517085-41-00 Phase II 1 country AstraZeneca AB
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo… Ended

2024-515660-31-00 Phase II 1 country Universitaetsklinikum Schleswig-Holstein AöR
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ… Ended

2024-511847-24-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity… Ended

2024-511511-25-00 Phase I/II 1 country UZ Leuven
ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) a… Ended

2024-514920-18-00 Phase I/II 1 country Institut Gustave Roussy
Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial Cancer. Ended

2024-513399-17-00 Phase III 2 countries AstraZeneca AB
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with adv… Ended

2023-510117-26-00 Phase II 1 country University College Dublin

Showing 25–35 of 35 trials

← All drugs A–Z